TP53 and Miyoshi myopathy: Another study using targeted sequencing compared different MM double-hit models, including the NCRI double-hit model, bi-allelic TP53 inactivation, and the mSMART 3.0 model, showed that double-hit MM accounted for 10.9%, 6.5%, and 15.2% of NDMM patients, respectively [30].